Stemness Characteristics of Fibrolamellar Hepatocellular Carcinoma: Immunohistochemical Analysis with Comparisons to Conventional Hepatocellular Carcinoma

被引:1
|
作者
Zenali, Maryam J. [1 ,2 ]
Tan, Dongfeng [3 ]
Li, Wei [1 ,2 ]
Dhingra, Sadhna [1 ,2 ]
Brown, Robert E. [1 ,2 ]
机构
[1] Univ Texas Hlth Sci Ctr Houston, Dept Pathol, Houston, TX 77030 USA
[2] Univ Texas Hlth Sci Ctr Houston, Dept Lab Med, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源
关键词
fibrolamellar hepatocellular carcinoma; cancer stem cells; CD133; CD44; PPAR-gamma; beta-catenin; Ki-67; Skp2; CELLS; CANCER; EXPRESSION; LIVER; THERAPY; CD133; PROLIFERATION; RESISTANCE; CAPACITY; SURVIVAL;
D O I
暂无
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
The involvement of cancer stem cells (CSC) in tumorigenesis has been studied in several malignancies, but their presence in fibrolamellar hepatocellular carcinoma (FLHCC) has not previously been evaluated. General characteristics of "stemness" include the expression of putative stem cell antigens, reduced cell cycle progression, and limited functional differentiation or dedifferentiation under the influence of the microenvironment. Immunohistochemical probes applied to 8 archival cases of FLHCC vis-a-vis contiguous non-neoplastic parenchyma, which was present in 5 cases, revealed such stemness characteristics by showing: (a) stem cell antigens, with moderate to intense expression of CD133 in the cytoplasm (6 of 8 FLHCC cases and comprising >40% of the tumoral areas) and of CD44 on the plasmalemmal aspect (7 of 8 FLHCC cases and comprising 50 to 95% of the tumor cells), vs foci of such overexpressions in only 1 of 5 of the contiguous liver parenchyma (p = 0.053 and p = 0.015, respectively); (b) limited G1 to S phase progression (<1% of tumor cells with nuclear S phase kinase-associated protein [Skp]2 expression); and (c) dedifferentiation or reduced functional differentiation in the form of minimal to absent expression of a differentiation-associated marker, peroxisomal proliferator-activator receptor (PPAR)-gamma in tumoral nuclei and loss of plasmalemmal expression of beta-catenin in 6 of 8 FLHCC cases vs expression of these proteins in the non-neoplastic, differentiated hepatocytes in 5 of 5 and 4 of 5 cases, respectively, in contiguous liver parenchyma (p <0.01 and p = 0.053, respectively). In contrast, only 1 of 11 cases of well-differentiated, conventional hepatocellular carcinoma (HCC) showed mild to moderate expression of CD133 in the cytoplasm, but with the majority (8 of 11) showing occasional nuclear expression. Similarly, only 3 of 11 cases of conventional HCC expressed plasmalemmal CD44. Notably, 11 of 11 cases of conventional HCC expressed beta-catenin on the plasmalemmal aspect of the tumor cells, and 3 of 11 showed nuclear translocation. These findings in conventional HCC were significantly different from those in FLHCC (p = 0.003, 0.009, and 0.0005, respectively). This study provides evidence of stemness in FLHCC and discusses the implications of stemness in the histogenesis of FLHCC vs conventional, well-differentiated HCC.
引用
收藏
页码:126 / 134
页数:9
相关论文
共 50 条
  • [1] Fibrolamellar Hepatocellular Carcinoma: An Immunohistochemical Comparison With Conventional Hepatocellular Carcinoma
    Abdul-Al, Hala M.
    Wang, Guanghua
    Makhlouf, Hala R.
    Goodman, Zachary D.
    INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY, 2010, 18 (05) : 313 - 318
  • [2] Immunohistochemical detection of procalcitonin in fibrolamellar hepatocellular carcinoma
    Kotaro Matsumoto
    Kentaro Kikuchi
    Ayako Hara
    Hiromichi Tsunashima
    Koichi Tsuneyama
    Shinpei Doi
    Clinical Journal of Gastroenterology, 2021, 14 : 827 - 830
  • [3] Immunohistochemical detection of procalcitonin in fibrolamellar hepatocellular carcinoma
    Matsumoto, Kotaro
    Kikuchi, Kentaro
    Hara, Ayako
    Tsunashima, Hiromichi
    Tsuneyama, Koichi
    Doi, Shinpei
    CLINICAL JOURNAL OF GASTROENTEROLOGY, 2021, 14 (03) : 827 - 830
  • [4] Molecular Characteristics of Fibrolamellar Hepatocellular Carcinoma
    Patonai, Attila
    Erdelyi-Belle, Boglarka
    Korompay, Anna
    Somoracz, Aron
    Torzsok, Peter
    Kovalszky, Ilona
    Barbai, Tamas
    Raso, Erzsebet
    Lotz, Gabor
    Schaff, Zsuzsa
    Kiss, Andras
    PATHOLOGY & ONCOLOGY RESEARCH, 2013, 19 (01) : 63 - 70
  • [5] Genomic analysis of fibrolamellar hepatocellular carcinoma
    Xu, Lei
    Hazard, Florette K.
    Zmoos, Anne-Flore
    Jahchan, Nadine
    Chaib, Hassan
    Garfin, Phillip M.
    Rangaswami, Arun
    Snyder, Michael P.
    Sage, Julien
    HUMAN MOLECULAR GENETICS, 2015, 24 (01) : 50 - 63
  • [6] Fibrolamellar Hepatocellular Carcinoma
    Shahi, Niharika
    Chung, Andrew David
    APPLIED RADIOLOGY, 2023, 52 (02) : 48A - 48C
  • [7] Fibrolamellar Hepatocellular Carcinoma
    Liu, Shu
    Chan, Kwok Wah
    Wang, Bingyuan
    Qiao, Liang
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2009, 104 (10): : 2617 - 2624
  • [8] Fibrolamellar hepatocellular carcinoma
    Smith, Mitchell T.
    Blatt, Ellen R.
    Jedlicka, Paul
    Strain, John D.
    Fenton, Laura Z.
    RADIOGRAPHICS, 2008, 28 (02) : 609 - 613
  • [9] Fibrolamellar hepatocellular carcinoma
    Koudah, Sabrina
    El Mouhadi, Sanaa
    Arrive, Lionel
    CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2012, 36 (01) : 5 - 6
  • [10] Fibrolamellar Hepatocellular Carcinoma
    Shigematsu, Yasuyuki
    Tanaka, Kazuhito
    Inamura, Kentaro
    INTERNAL MEDICINE, 2025,